An important milestone in the genomic era was reached in February 2001, when
the Human Genome Project and Celera Genomics presented the initial sequencing
and analysis of the human genome. Biotechnology in the post-genomic era looks
set to change the way in which medicine is practiced, as well as the way in
which drugs and diagnostics are discovered and developed. Many exciting and
fast-evolving technological advances are being employed to transform the raw
sequence data into new treatments and diagnostics. 'The Outlook for the
Biotech Sector in the Post-Genomic Era: Strategies for drug discovery,
diagnostics and personalized medicine', explores the impact of genomics,
transcriptomics and proteomics and identifies both scientific and commercial
opportunities in genomic technology. As the focus of drug development in post-genomic
markets shifts towards preventive and personalized medicine, this report
analyzes the allocation of research resources and identifies where the greatest
return on R&D investment may be achieved. As a decision-making support, this
report will enable pharma and biotech executives to act quickly in securing a
competitive edge.
View Cart
